COMPARATIVE ANALYSIS OF MODERN ORAL HYPOGLYCEMIC AGENTS: EFFICACY, SAFETY, AND POTENTIAL PANCREATIC PROTECTIVE EFFECTS
Keywords:
Type 2 diabetes mellitus; oral glucose-lowering agents; metformin; SGLT2 inhibitors; DPP-4 inhibitors; sulfonylureas; beta-cell function; pancreatic protection; hypoglycemia.Abstract
Type 2 diabetes mellitus is a progressive metabolic disorder characterized by systemic insulin resistance in peripheral target tissues accompanied by an unrelenting, gradual deterioration of pancreatic beta-cell functional reserve and secretory competence. Consequently, contemporary pharmacological intervention has transitioned beyond the narrow objective of lowering circulating blood glucose concentrations toward a comprehensive strategy prioritizing glycemic durability, therapeutic safety, cardiovascular and renal event mitigation, and the potential structural preservation of the endocrine pancreas. This comparative analysis reviews the foundational and contemporary oral glucose-lowering pharmacological classes currently deployed in clinical practice: biguanides (metformin), sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas. While sulfonylureas achieve prompt initial decrements in glycated hemoglobin, their non-glucose-regulated stimulation of the secretory apparatus accelerates functional beta-cell burnout while conferring substantial risks of severe hypoglycemia and weight gain. Metformin remains a primary foundational cornerstone due to its proven glycemic reduction, low intrinsic hypoglycemic liability, and favorable body weight trajectory. Sodium-glucose cotransporter-2 inhibitors provide moderate glucose reduction while delivering substantial cardiorenal protective benefits, modest body weight loss, and systemic blood pressure reduction. Dipeptidyl peptidase-4 inhibitors demonstrate excellent patient tolerability, weight neutrality, and minimal hypoglycemic vulnerability. Mechanistic investigations indicate that modern classes, particularly incretin enhancers and renal glucose clearance blockers, alleviate glucotoxicity, oxidative stress, and apoptotic pathways within the islets of Langerhans; however, these experimental cytoprotective observations must be distinguished from clinically verified human endpoints. Optimal treatment requires an individualized patient-centered approach that aligns pharmacological properties with metabolic phenotypes.
References
1.American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl. 1):S158–S178. doi:10.2337/dc24-S009.
2.Bailey CJ. Metformin: historical overview and modern pharmacology. Diabetologia. 2017;60(9):1566–1576. doi:10.1007/s00125-017-4318-z.
3.Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110. doi:10.2337/diabetes.52.1.102.
4.Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034.
5.Del Prato S. Role of glucotoxicity and lipotoxicity in the etiology of type 2 diabetes and beta-cell dysfunction. Am J Cardiol. 2009;104(10):42D–49D. doi:10.1016/j.amjcard.2009.09.006.
6.Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, benefits, and liabilities. Lancet Diabetes Endocrinol. 2022;10(11):812–824. doi:10.1016/S2213-8587(22)00210-4.
7.Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi:10.1056/NEJMoa2024816.
8.Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443. doi:10.1056/NEJMoa066224.
9.Nauck MA, Meier JJ. Incretin hormones and their role in type 2 diabetes therapy. Diabetes Obes Metab. 2023;25(Suppl. 1):5–21. doi:10.1111/dom.15112.
10.Takahara M, Shiraiwa T, Matsuoka TA, Katakami N, Shimomura I. Amelioration of pancreatic beta-cell dysfunction following SGLT2 inhibitor treatment in experimental diabetic models: a systematic review. Front Endocrinol (Lausanne). 2023;14:1124589. doi:10.3389/fendo.2023.1124589.
